Lilly, BI's Jardiance still beats Novo's Rybelsus when it comes to cost-effectiveness: ICER

1st November 2019 Uncategorised 0

ICER started giving Novo Nordisk a hard time about the cost-effectiveness of its oral version of semaglutide, Rybelsus, before the drug was even approved in September. Now the product has its price tag—$772 per month, on par with comparable injectables—yet ICER still isn’t happy.

More: Lilly, BI's Jardiance still beats Novo's Rybelsus when it comes to cost-effectiveness: ICER
Source: fierce